The Big Question 

What if we had therapies to extend healthspan and prevent the onset of age-related diseases? 

The Problem 

Despite recent increases in average lifespan across the U.S., there has not been a corresponding increase in healthspan – the amount of time a person remains in good health and free from long-term disease or disability. Currently, 80% of all adults over the age of 65 have at least one chronic condition, and 30% of the same population are considered “pre-frail,” which is associated with a higher risk of mortality in the next five years. Americans with symptoms of aging such as fatigue, reduced cognitive ability, pain, reduced hearing and vision, and sleep disruption have very few treatment options. With this aging demographic expected to only increase, health care costs will rise significantly.

The Solution

In response to these issues, the PROactive Solutions for Prolonging Resilience (PROSPR) program aims to identify biochemical and physiological markers and develop assessment tools that will allow researchers to better understand and target the underlying causes of age-related disease. To achieve this goal, PROSPR will pioneer in-home data collection and clinical trial protocols that can assess age-associated health outcomes in just three years instead of decades of study, accelerating the availability of new therapies. If successful, PROSPR will build a new therapeutic industry with interventions focused on maintaining health during aging.

Why ARPA-H?

A revolutionary approach to extending the healthspan of people across the U.S. requires a comfort with calculated research that only a funding agency such as ARPA-H can provide.